Evidence map›Paper›PMID 31406533›Full record

ArticleOpen access Macedonian journal of medical sciences2019

The Correlation of

Meike Rachmawati, Herry Yulianti, Bethy S Hernowo, Sri Suryanti, Indra Wijaya, Nur Rahadiani, Didik S Heriyanto, Irianiwati Irianiwati

Open access · diamondAbstract read
In one paragraph

Article in Open access Macedonian journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Effect ofFrontiers in cell and developmental biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Meike RachmawatiDepartment of Pathology Anatomy, Oncology and Stem Cells Research Centre, Padjadjaran University, Dr Hasan Sadikin Hospital, Bandung, Indonesia.
Herry YuliantiDepartment of Pathology Anatomy, Oncology and Stem Cells Research Centre, Padjadjaran University, Dr Hasan Sadikin Hospital, Bandung, Indonesia.
Bethy S HernowoDepartment of Pathology Anatomy, Oncology and Stem Cells Research Centre, Padjadjaran University, Dr Hasan Sadikin Hospital, Bandung, Indonesia.
Sri SuryantiDepartment of Pathology Anatomy, Oncology and Stem Cells Research Centre, Padjadjaran University, Dr Hasan Sadikin Hospital, Bandung, Indonesia.
Indra WijayaDepartment of Interne Medicine, Padjadjaran University, Dr Hasan Sadikin, Hospital Bandung, Bandung, Indonesia.
Nur RahadianiDepartment of Pathology Anatomy, Indonesia University, Cipto Mangun Kusumo Hospital, Jakarta, Indonesia.
Didik S HeriyantoDepartment of Pathology Anatomy, Gajah Mada University, Sardjito Hospital, Jogjakarta, Indonesia.
Irianiwati IrianiwatiDepartment of Pathology Anatomy, Gajah Mada University, Sardjito Hospital, Jogjakarta, Indonesia.
Dr. Hasan Sadikin General Hospital · IDUniversitas Gadjah Mada · IDUniversity of Indonesia · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal Adenocarcinoma (ADCCR) is the third most cancer not only in the world but also in Indonesia. There were 623 cases of ADCCR at Dr Hasan Sadikin hospital within 2015-2017. Both KRAS and TP53 mutation are known as genes which involve in carcinogenesis through the same pathway, namely the chromosomal instability pathway. In West Java, researches focusing on mutation KRAS and p53 also a correlation between both biomarkers among ADCCR patients are still limited.

aimTherefore, this research aimed to perceive a correlation between KRAS gene expression with p53 immunoexpression in ADCCR.

methodsCross section research design was performed to 62 cases of ADCCR as paraffin block taken from 4 hospitals in West Java, including Dr Hasan Sadikin hospital Bandung, Santosa hospital Bandung, Borromeus hospital Bandung and Syamsudin hospital Sukabumi from January 1st 2014 to 31s November 2018. KRAS mutation gene data taken from secondary data at molecular laboratory in Ciptomangunkusumo Hospital Jakarta and Dr Sardjito Hospital Jogjakarta, while the detection of p53 immunoexpression data using immunohistochemical staining was carried out in the Laboratorium of Anatomical Pathology of Padjadjaran University (Dr Hasan Sadikin Hospital). All data were analysed using Chi-Square test with p-value < 0,05 of significant level then proceeded with Stata ver.11 for windows.

resultsThe results of this study showed that KRAS gene expressions from 62 sample consist of 39 wild type KRAS (62.39%) and 23 mutant KRAS (37.1%). The p53 immunoexpression consists of 27 negative cases (non-mutant p53) and 35 mutant p53, which includes 10 cases as focal expression (16.33%) and 25 cases as diffuse expressions (40.33%). There is a significant association between KRAS gene expression and p53 immunoexpressions in ADCCR (p = 0.04), with mild positive correlation (Rho 0.28).

conclusionThis study concluded that KRAS and p53 mutations are involved in carcinogenesis, and the p53 mutation is a more dominant risk factor than KRAS mutation among West Java people. P53 mutations with diffuse pattern tend to express mutant KRAS while p53 negative and having a focal pattern tend to express wt KRAS.

Indexed as

Adenocarcinoma Colorectal (ADCCR)KRASp53

Identifiers

PMID31406533
PMCPMC6684412
OpenAlexW2956377476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.